TriSalus Reports Q2 2024 Financial Results and Business Update
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/22/2026
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- UBS says bull market has further to run
- S&P 500 may pull back before midterms, but Citi says buy the dip
- Global yield relief evaporates as U.S. rates push back toward multi-decade peaks
- BofA's Hartnett sees dollar slump, risk selloff if bond intervention fails
- Applied Optoelectronics sets up $600M at-the-market stock offering
- Fannie Mae loses at least 10 senior executives amid departures - WSJ
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- Morgan Stanley course-corrects their semiconductor equipment outlook on demand
- One killed, three injured when man attacks Swedish school with sword
Jones Trading Reiterates Buy Rating on TriSalus Life Sciences, Inc. (TLSI)
August 16, 2024 2:54 PM EDTJones Trading analyst Justin Walsh reiterated a Buy rating and $11.00 price target on TriSalus Life Sciences, Inc. (NASDAQ: TLSI)
The analyst comments "Nelitolimod delivered with the TriNav system will provide clinical benefit to patients with amenable solid tumors. TriNav will continue... More
